^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anti-MUC1 CAR-T cells

    i
    Associations
    News

    Trials

    Company:
    Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology
    Drug class:
    MUC1-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer (NCT03706326)
    Phase 1/2
    The First Affiliated Hospital of Guangdong Phar...
    Unknown status
    Last update posted :
    10/16/2018
    Initiation :
    09/28/2018
    Primary completion :
    09/28/2021
    Completion :
    09/28/2021
    PD-1
    |
    MUC1 expression
    |
    anti-MUC1 CAR-T cells
    Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC (NCT03525782)
    Phase 1/2
    The First Affiliated Hospital of Guangdong Phar...
    Unknown status
    Last update posted :
    05/16/2018
    Initiation :
    02/01/2018
    Primary completion :
    01/31/2021
    Completion :
    01/31/2022
    PD-1
    |
    MUC1 expression
    |
    Keytruda (pembrolizumab) • anti-MUC1 CAR-T cells